Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · ImmunityBio, Inc. (IBRX)

ImmunityBio: ANKTIVA plus BCG meets primary endpoint in BCG-naive bladder cancer trial

Positive Impact 4 of 5 product/contract

ImmunityBio said its ANKTIVA plus BCG combination met the primary efficacy endpoint in Cohort A of the randomized QUILT-2.005 trial in BCG-naive non-muscle invasive bladder cancer, with 370 subjects. The company plans to submit a supplemental Biologics License Application to the FDA by year-end 2026, which could expand ANKTIVA's indication to earlier-stage patients.

Key points

  • Trial of 370 subjects compared ANKTIVA plus BCG with BCG alone; the combination showed a statistically significant efficacy improvement in carcinoma in situ patients.
  • No treatment-related deaths were reported; common adverse events were consistent with BCG alone.
  • Supplemental BLA is on track for FDA submission by year-end 2026; more study details will be presented at an upcoming medical congress.

The filing

CompanyImmunityBio, Inc. (IBRX)
Form8-K, current report
Filed with the SECNov 9, 2026, 6:33 AM ET
Accession number0001326110-26-000091

Items reported: 7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 7:05 AM ET, from this filing only.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.